PIVYA
Growthpivmecillinam
NDAORALTABLETPriority Review
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
PIVYA (pivmecillinam) is [see microbiology ( )] . First approved in 2024.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PIVYA (pivmecillinam) is an oral tablet antibiotic approved in April 2024 for bacterial infections. It is a mecillinam derivative that inhibits bacterial cell wall synthesis through penicillin-binding protein inhibition. The drug represents a new oral formulation option in the beta-lactam antibiotic class.
Growth
Early-stage growth product with moderate competitive pressure (30%), indicating active market development phase requiring investment in field infrastructure and market education.
Mechanism of Action
[see Microbiology ( )] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection
Started Sep 2022
299 enrolled
Uncomplicated Urinary Tract Infection
Career Relevance
PIVYA is a newly approved, early-stage growth product with minimal linked job visibility, suggesting either early pipeline establishment or niche market focus. Roles will center on commercial launch execution, competitive positioning against established antibiotics, and rapid market adoption.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.